ArticleFrontiers in public health2026
Cost-utility and price threshold analysis of sacituzumab tirumotecan versus single-agent chemotherapy for previously treated metastatic triple-negative breast cancer in China.
Liman Huo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.